Since GSPE acts as a regulator of the Keap1/Nrf2/ARE signaling pathway [12], we hypothesized that the Nrf2/HO-1 signaling pathway could serve as a potential therapeutic target for GSPE to delay the progression of DKD. This evidence concerns the gene NFE2L2 and diabetic kidney disease.